Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer
Abstract Introduction This Phase I study evaluated the safety, tolerability and efficacy of olaparib, a potent oral poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). Methods Eligible patients who had receiv...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 语言: | 英语 |
| 出版: |
2013
|
| 在线阅读: | https://doi.org/10.1186/bcr3484 https://breast-cancer-research.biomedcentral.com/counter/pdf/10.1186/bcr3484 |
| 标签: |
添加标签
没有标签, 成为第一个标记此记录!
|